Papillomavirus cancer risk. Ai fost blocat(ă) temporar
Source: ORL. Human papillomavirus has been proven to be an important risk factor for head and neck cancer, besides anogenital cancers. Although gynecological HPV malignancies have been intensely studied and documented, men can also be affected by HPV-related cancers — i.
Traditionally, oropharyngeal cancers have been linked to tobacco and alcohol use, but the last decades have shown an increased incidende of HPV-associated oropharyngeal cancers, especially oropharyngeal squamous cell carcinomas. The vaccination programs along the world aim to reduce the incidence of anogenital cancers, as well as to protect against oropharyngeal HPV-associated cancers. The use of prophylactic vaccines that are highly immunogenic will likely decrease the incidence of HPV-associated cancers in the following years.
The therapeutic vaccines are designed to generate cell-mediated immunity against tumoral cells by using different techniques — i. The awareness about this health issue, the development of prophylactic methods, along with vaccines and the further development of accurate and available screening methods will offer an opportunity to achieve better survival rates in HPV-induced oropharygeal cancers.
Copyright of ORL. However, users may print, download, or email articles for individual use. This abstract may be abridged.
No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.
Datorită răspândirii mari a HPV-ului se consideră că și un singur contact sexual în viață poate fi suficient pentru a contracta un virus oncogen și din acest motiv orice femeie care a avut vreodată un contact sexual trebuie testată.
Important User Information: Remote access to EBSCO's databases is permitted to patrons of subscribing institutions accessing from remote locations for personal, non-commercial use. However, remote access to EBSCO's databases from non-subscribing institutions is not allowed if the purpose of the use is for commercial gain through cost papillomavirus cancer risk or avoidance for a papillomavirus cancer risk institution.